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Recent advances in allogeneic hematopoietic stem cell transplantation have led to increasing use of this
modality in older patients who tend to have been more heavily pretreated and have more comorbidities.
Thus, the evaluation of comorbidity is of increasing importance to more precisely assess the beneﬁts and
risks of the transplantation procedure. Researchers from Seattle developed the hematopoietic cell trans-
plantationespeciﬁc comorbidity index (HCT-CI), which was associated with the risk of mortality in several
retrospective studies. However, its clinical utility has not been extensively documented in prospective
studies. The aim of the present study was to evaluate the utility of the HCT-CI prospectively in a multi-
center setting. Overall survival (OS) and nonrelapse mortality (NRM) at 2 years were 59% and 20%,
respectively (n ¼ 243). We found that the HCT-CI in its original scale failed to predict OS and NRM in this
set of patients. Thus, we applied a ﬂexible HCT-CI risk scoring system (restratifying scores from 0 to 3 to
indicate low risk, and scores of 4 or higher as high-risk). The ﬂexible HCT-CI was found to predict 2-year
NRM and OS better than the original HCT-CI (NRM: P ¼ .01, OS: P ¼ .003). In subgroup analysis, we
evaluated the usefulness of the original HCT-CI for patients excluding those who received cord blood
transplantation (n ¼ 186). Both 2-year OS and 2-year NRM were not signiﬁcantly different according to
the original HCT-CI (P ¼ .304, P ¼ .996), but with the ﬂexible HCT-CI, there were signiﬁcant differences in
2-year OS and 2-year NRM (P ¼ .005 and P ¼ .005, respectively). Multivariate analysis identiﬁed age >50,
performance status (PS) <90, donor type (HLA-mismatched/unrelated donor), and the ﬂexible HCT-CI 4
as signiﬁcant predictors for worse OS at 2 years. However, the ﬂexible HCT-CI did not remain a signiﬁcant
predictor for NRM at 2 years in multivariate analysis, whereas age, PS, and donor type did. The HCT-CI did
not consistently predict both NRM and OS, but it still can be a useful tool in combination with otherdgments on page 1558.
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Patient and Disease Characteristics
Characteristic
Total patients
Age at transplantation, median (
Diagnoses
AML
ALL
MDS
Lymphoma
CML
AA
ATL
MF
MM
Disease risk
High
Intermediate
Remission status at transplantati
High
Low
Conditioning regimens
MAC
RIC
Donors
Related
Unrelated
Hematopoietic cell source
BM
CBT
PB
AML indicates acute myeloid leu
MDS, myelodysplastic syndrome;
aplastic anemia; ATL, adult T cell leu
myeloma; BM, bone marrow; CBT,
Data presented are n unless otherwfactors, such as PS and age. Furthermore, the HCT-CI, although potentially useful for capturing pre-
transplantation comorbidity and risk assessment, may need further validation before its adoption for
routine clinical use.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION 16 years old for malignant or nonmalignant hematologic disease as eligible
Understanding the impact of speciﬁc pretransplantation
variables on the risk of mortality, especially nonrelapse
mortality (NRM), after allogeneic hematopoietic stem cell
transplantation (HSCT) is of the utmost importance for
deciding which patients will beneﬁt most from this high-risk
procedure. In 2005, Sorror et al. developed and validated the
most popular HSCT-speciﬁc index, the hematopoietic cell
transplantationespeciﬁc comorbidity index (HCT-CI), inten-
ded to quantify the impact of a patient’s pretransplantation
comorbidities on post-transplantation outcome [1].
Since its creation, various studies have attempted to
validate the HCT-CI in different disease-speciﬁc settings [2-
13]. Its ability to predict survival and NRM has differed be-
tween studies, and its ability has not been conﬁrmed in all of
them. Furthermore, it has not been fully validated in pro-
spective multicenter studies and its predictive value remains
to be elucidated in the Japanese population.
Therefore, the primary aim of the present study was to
independently validate the HCT-CI calibration and discrimi-
nation in a multicenter prospective study setting. As a sec-
ondary aim, we evaluated its usefulness in Japanese patients.METHODS
Patients
Per protocol, we considered only ﬁrst transplantations performed using
peripheral blood stem cells, bone marrow, or cord blood cells on patients Value
243
range), yr 45.3 (16-74)
102
45
39
20
9
9
8
6
5
139
104
on
37
206
166
77
68
175
156
57
30
kemia; ALL, acute lymphoid leukemia;
CML, chronic myeloid leukemia; AA,
kemia; MF, myeloﬁbrosis; MM,multiple
cord blood; PB, peripheral blood.
ise indicated.for analysis. Written informed consent was obtained from all patients before
registration. The study was approved by the institutional review board of
each participating center and was conducted in accordance with the
Declaration of Helsinki.
Comorbidity Scoring System
Pretransplantation comorbidities were scored according to the original
HCT-CI before conditioning started in all patients, who were then followed
for 2 years or until relapse or death, if earlier than 2 years after trans-
plantation. Of the 244 patients, complete clinical data allowing assessment
of HCT-CI were available in 243. One patient with incomplete information
was excluded from the analysis. Although the original HCT-CI uses a deﬁ-
nition of pulmonary dysfunction based on subjective symptoms or the re-
sults of respiratory function testing, we modiﬁed it to use only the results of
the latter, to deﬁne pulmonary dysfunction more precisely and eliminate
bias between facilities in diagnosing pulmonary comorbidity. The respira-
tory function test was performed in all patients but 1. According to the
original HCT-CI, patients were divided into 3 groups: low (score ¼ 0), in-
termediate (1 and 2), and high (3), as previously reported.
Transplantation
According to the European Group for Blood andMarrow Transplantation
(EBMT) criteria [14], we considered regimens with a total busulfan dose
>8 mg/kg, cyclophosphamide dose >120 mg/kg (or >60 mg/kg, if in com-
bination with other drugs), or total body irradiation >6 Gy as myeloablative
conditioning (MAC). Reduced-intensity conditioning (RIC) regimens were
ﬂudarabine-based with or without low-dose total body irradiation (4 Gy).
Disease Risk and Remission Status at Transplantation
As described by Sorror et al. [1], we categorized disease risk as low or
high. Low-risk diseases were deﬁned as chronic myeloid leukemia in ﬁrst
or second chronic phase, aplastic anemia, acute leukemia in ﬁrst or second
complete remission, myelodysplastic syndrome in refractory anemia or
refractory anemia with ring sideroblasts, and chemosensitive lymphoma
or multiple myeloma. All other conditions were classiﬁed as high-risk
diseases.
Statistical Methods
The primary endpoints for this analysis were the cumulative incidence
of NRM and OS 2 years after allogeneic HSCT. Probabilities of NRM and OS
were calculated using the Kaplan-Meier method, and the log-rank test was
used for univariate comparisons. The Cox regression model was used for
multivariate analysis to identify prognostic factors among variables that
included age, performance status (PS), disease risk, remission status at the
time of HSCT, donor type, and the HCT-CI. Stepwise selection algorithmwas
applied for model selection using as criteria P ¼ .10 for variable entry.
Relative risk with 95% conﬁdence interval and P value were determined
from these analyses. All P values were 2-sided, with the type 1 error rate
ﬁxed at .05. Statistical analyses were performed with SAS software version
8.2 (SAS institute, Cary, NC).Figure 1. Distribution of HCT-CI. The distribution of HCT-CI scores is found to
be essentially the same in Japanese patients as reported in the original study.
Table 2
Prevalence of Comorbidities
Comorbidity Prevalence
Pulmonary (mild) 67 (27.5)
Pulmonary (severe) 59 (24.2)
Hepatic (mild) 35 (14.4)
Infection 22 (9.0)
Psychiatric 11 (4.5)
Diabetes 8 (3.2)
Hepatic (moderate/severe) 6 (2.4)
Solid tumor 6 (2.4)
Data presented are n (%).
Compared with the original report, our study cohort has a larger
proportion of patients with pulmonary comorbidity.
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Patient Characteristics
In this study, 243 consecutive patients with a variety of
hematological disorders who underwent allogeneic HSCT
from 2007 to 2009 in 14 facilities of the Kanto Study Group
for Cell Therapy in Japan were enrolled. Diagnosis and other
details of the patients are summarized in Table 1. TheFigure 2. Two-year OS/NRM using the original HCT-CI scoring system. (A) Shows OS
predict OS and NRM at 2 years in our cohort.median age at transplantation was 45.3 years (range, 16 to
74 years). A total of 166 patients received MAC and 77
received RIC. The stem cell sources included bone marrow
(n¼ 156), peripheral blood (n¼ 30), and cord blood (n¼ 57).
Sixty-eight patients received a transplant from a related
donor and 175 from an unrelated donor. The most frequent
diagnosis was myeloid malignancies (acute myeloid leuke-
mia/myelodysplastic syndrome; 58.2%), followed by acute
lymphoblastic leukemia (18.4%) and non-Hodgkin lym-
phoma (10.7%).HCT-CI
The distribution of HCT-CI scores was found to be essen-
tially the same in Japanese patients as reported in the orig-
inal study (Figure 1). The distribution of the comorbidities
represented in the HCT-CI score is shown in Table 2. Themost
frequent comorbidities were mild or severe pulmonary
comorbidities (51.9%), followed by mild hepatic comorbidity
(14.6%) and active infections (9.3%). The other comorbidities
observed in this cohort included psychiatric problems (4.8%),(P ¼ .44) and (B) NRM (P ¼ .96). The original HCT-CI scoring system fails to
Figure 3. Two-year OS/NRM using the ﬂexible HCT-CI scoring system. (A) Shows OS (P ¼ .003) and (B) shows NRM (P ¼ .01). The ﬂexible HCT-CI has a better predictive
capacity for NRM and OS at 2 years than the original HCT-CI.
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(2.8%), and solid tumors (2.8%). The original HCT-CI scoring
system failed to predict OS (P ¼ .44) and NRM (P ¼ .96) at
2 years in our cohort (Figure 2). When outcome was plotted
according to the number of individual HCT-CI scores, 2 risk
groups emerged. We, therefore, applied the ﬂexible HCT-CI
risk scoring system (scores of 0 to 3 were restratiﬁed
as low risk and scores 4 as high-risk). Thus, we grouped
our patients into 2 risk categories (low and high). The dis-
tribution of the ﬂexible HCT-CI did not differ signiﬁcantly for
age at the time of transplantation (younger versus older than
50 years), source of transplanted stem cells (bone marrow
versus peripheral blood versus cord blood), or conditioning
regimen (MAC versus RIC). The superior predictive capacity
of the ﬂexible HCT-CI for NRM (P ¼ .01) and OS at 2 years
(P ¼ .003) compared with the original HCT-CI was conﬁrmed
(Figure 3).Comparing the prognostic value of the original HCT-CI
with the ﬂexible HCT-CI using the Cox regression model
and likelihood ratio test, there was a signiﬁcantly higher
predictive power for both NRM (likelihood ratio test: 5.12,
P < .001) and OS at 2 years (likelihood ratio test: 7.00,
P < .001) using the ﬂexible HCT-CI.
Outcome and Cause of Death
The OS and NRM of all patients were 59% and 20% at
2 years, respectively. The most common cause of NRM was
infection. Although the distribution of the HCT-CI was not
associated with any causes of NRM, patients with a score  3
were more likely to die from infection (data not shown).
Multivariate Analysis
Multivariate analysis identiﬁed age (>50) (P ¼ .01, hazard
ratio [HR], 1.80), PS (<90) (P ¼ .002; HR, 2.57), donor type
Table 3
Multivariate Analysis
Factor Two-Year OS Two-Year NRM
HR (95% CI) P Value HR (95% CI) P Value
Age
50 1 1
>50 1.80 (1.14-2.84) .01 2.17 (1.14-4.12) .017
Sex
M 1 1
F .91 (.60-1.36) .65 .82 (.46-1.45) .5
PS
90 1 1
<90 2.57 (1.38-4.79) .002 4.60 (2.12-9.99) .0001
Disease risk
Low 1 1
High 1.25 (.81-1.93) .3 .92 (.50-1.69) .8
Conditioning
MAC 1 1
RIC .70 (.43-1.13) .14 .61 (.31-1.18) .1448
Donor type
MRD 1 1
Not 1.82 (1.08-3.06) .02 2.80 (1.18-6.64) .0189
HCT-CI score
0-3 1 1
4 1.82 (1.10-3.01) .019 1.65 (.81-3.36) .165
Multivariate analysis identiﬁed age (>50), PS (<90), donor type (HLA-mis-
matched/unrelated donor), and ﬂexible HCT-CI score (4) as signiﬁcant
predictors for worse OS at 2 years. However, ﬂexible HCT-CI score does not
remain a signiﬁcant predictor for NRM at 2 years, whereas age, PS, and
donor type did remained as signiﬁcant predictors.
95% CI indicates 95% conﬁdence interval; MRD, HLA-matched related donor.
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the ﬂexible HCT-CI score (4) (P ¼ .019; HR, 1.82) as signiﬁ-
cant predictors of worse OS at 2 years (Table 3). However, the
ﬂexible HCT-CI was not a signiﬁcant predictor of NRM at
2 years, in contrast to age (P ¼ .017; HR, 2.17), PS (P ¼ .0001;
HR, 4.60) and donor type (P ¼ .0189; HR, 2.80).
Subgroup Analysis
As Sorror’s original study excluded cord blood trans-
plantations, we evaluated the usefulness of the original HCT-
CI for patients excluding cord blood recipients (n ¼ 186).
Both 2-year OS and 2-year NRM were not signiﬁcant
different according to the original HCT-CI (P ¼ .304, P ¼ .996,
respectively), but with the ﬂexible HCT-CI, there were sig-
niﬁcant differences in 2-year OS and 2-year NRM (P ¼ .005
and P ¼ .005, respectively) (Figure 4).
DISCUSSION
We originally planned to independently validate the HCT-
CI, a widely used prognostic tool originally proposed in 2005,
the usefulness of which has been subsequently reported only
in studies based on limited, retrospective, and mostly single-
center patient series. For this study, we prospectively
enrolled unselected patients consecutively undergoing allo-
geneic HSCT in Japan and evaluated the predictive ability of
the HCT-CI for NRM and OS, applying the same selection
criteria originally used by Sorror et al.
We found no predictive value for OS and NRM using the
original HCT-CI. We then applied a ﬂexible HCT-CI risk
scoring system (restratifying those with a score of 0 to 3 as
low risk and those with a score  4 as high risk). We found
that this ﬂexible HCT-CI did have predictive capacity for NRM
and OS at 2 years. Furthermore, multivariate analysis iden-
tiﬁed age (>50), PS (<90), donor type (HLA-mismatched/
unrelated donor), and the ﬂexible HCT-CI (4) as signiﬁcant
predictors of worse OS at 2 years. However, the ﬂexible HCT-CI did not appear to be a signiﬁcant predictor for NRM at
2 years, whereas age, PS, and donor type were signiﬁcant
predictors. Compared with the original report, our study
cohort had a larger prevalence of pulmonary comorbidity
(51.9% versus 33%). We assume that the sensitivity of
detecting this in our study was higher than in the original
study because we used respiratory function testing to cap-
ture pulmonary comorbidity. We think it is very useful to
evaluate the respiratory function in this way, to determine
pulmonary comorbidity more accurately. However, this may
result in a requirement to modify scoring because of the
higher sensitivity of respiratory function testing when
applied as the only criterion of pulmonary dysfunction. Renal
dysfunction is deﬁned by creatinine levels, but these are
gender sensitive and also vary between facilities. Creatinine
levels > 1.2 mg/dL (the reference value in the original deﬁ-
nition) indicate that the glomerular ﬁltration rate has already
decreased signiﬁcantly. Therefore, creatinine levels do not
reﬂect renal dysfunction correctly. We would like to propose
the use of creatinine clearance instead. In our cohort, the
score distribution was almost the same as in the original
study, but the frequencies of comorbidities were different.
Some comorbidities, such as obesity, occur less frequently in
Japan than in Western countries. Racial differences are
evident in the distribution of the particular comorbidity in
scale. We may have to re-examine the distribution of the
score and reconsider certain items for a more appropriate
Japanese scale.
About 85% of patients were included in the score from0 to
3 group. Patients in this group had similar outcomes,
regardless of any differences in the score, possibly because of
a strong inﬂuence of the high prevalence of pulmonary co-
morbidity. More than 50% of patients were assessed as hav-
ing pulmonary dysfunction; undoubtedly, some cases were
included where pulmonary dysfunction did not directly
affect the prognosis. Barba et al. reported that 85% of patients
were considered to be suffering from pulmonary comorbid-
ity in their cohort [15]. They found no predictive value of the
original score, and, therefore, used a different risk group
stratiﬁcation. With the aim of including a sufﬁcient number
of patients in each risk group, they decided to use a modiﬁed
HCT-CI, in which patients were classiﬁed into low (score 0 to
3), intermediate (4 and 5), and high risk (6). They suggest
that modiﬁed HCT-CI has better predictive capacity for 2-
year NRM than the original HCT-CI. There are a few reports
employing modiﬁed-risk group stratiﬁcation because the
original cut-off points failed to yield any signiﬁcant differ-
ences [16,17]. That is, if the frequency of the comorbidity is
different from the original study, the original cut-off points
may no longer be applicable. Because the prevalence of co-
morbidity depends on the patient’s background, the cut-off
points may need to be changed according to the character-
istics of the patient population.
Considering regional and racial differences in the preva-
lence and severity of comorbidities, the HCT-CI tool required
validation in non-Western countries, as well. Three retro-
spective Japanese studies on the HCT-CI were previously
reported. Maruyama et al. assessed 132 transplantation pa-
tients with nonecomplete remission. A higher HCT-CI score
was associated with increased risk of NRM and poor OS. That
study was valuable in that it demonstrated that the HCT-CI
could be applicable in Japan [18]. Kataoka et al. investi-
gated the usefulness of the HCT-CI with 187 patients who
underwent transplantation. They classiﬁed patients into 2
groups, according to disease risk. The HCT-CI was associated
Figure 4. Two-year OS/NRM in patients excluding cord blood recipients. (A) Shows OS by the original HCT-CI (P ¼ .304). (B) Shows NRM by the original HCT-CI
(P ¼ .996). (C) Shows OS by the ﬂexible HCT-CI (P ¼ .005). (D) Shows NRM by the ﬂexible HCT-CI (P ¼ .005). The ﬂexible HCT-CI has a better predictive capacity
for NRM and OS at 2 years than the original HCT-CI in patients excluding cord blood recipients.
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high-risk patients. Regarding the prevalence of comorbidity,
hepatic dysfunction was most common (42%), followed by
pulmonary dysfunction (35%) [19]. Takasaki et al. examined
71 transplantation patients over 50 years of age. A high HCT-
CI (3) was signiﬁcantly associated with worse OS and NRM
at 5 years. In that study, the most frequent comorbidity was
pulmonary comorbidity (39%), followed by infection (23%)
[20]. More recently, 2 large prospective studies were carried
out to assess the usefulness of this scale [21,22]. In agreement
with previous reports, the HCT-CI was 1 of several signiﬁcant
prognostic factors, but it was not consistently predictive.
According to our multivariate analysis, the HCT-CI may be a
useful predictive tool in combinationwith other factors, such
as PS and age.
Our study has the typical limitation of a small sample size
and relatively short duration of follow-up. Statistical power
is low because of our small sample size. We cannot deny that
signiﬁcant differences did not become apparent because of
the low power. Hence, it is difﬁcult to draw any deﬁnitive
conclusions. Nevertheless, the observed data demonstrate
that the HCT-CI is useful for assessing the role of comorbidity
information in clinical risk-adapted decision-making for
HSCT candidates.
In conclusion, the HCT-CI is a simple novel tool that
considers the presence or absence of pretransplantation
comorbidities to predict the risk of death from
transplantation-related complications. It has the potential
for widespread applicability, both in clinical practice and in
clinical trials in Western countries. However, someinvestigators have already shown that the HCT-CI may not
useful for all the different possible allogeneic HSCT settings,
such as different disease types, transplantation procedures,
and donors, as well as the patient’s risk proﬁle [6-30]. Thus,
a possible weakness of all current models may be related to
their not having the same impact in different patient and
transplantation populations. The HCT-CI, although a useful
tool for capturing pretransplantation comorbidity and risk
assessment, needs to be further validated before adopting it
for routine clinical use.
ACKNOWLEDGMENTS
This paper was presented in part as a poster at the 54th
Annual Meeting of the American Society of Hematology,
Atlanta, Georgia, December 2012.
The authors thank the medical, nursing, data processing,
and laboratory staff at the Kanto Study Group for Cell Ther-
apy in Japan for their valuable contributions to this study
through dedicated care of the patients.
Financial disclosure: The authors have nothing to disclose.
Conﬂict of interest statement: There are no conﬂicts of in-
terest to report.
REFERENCES
1. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation
(HCT)-speciﬁc comorbidity index: a new tool for risk assessment before
allogeneic HCT. Blood. 2005;106:2912-2919.
2. Lim ZY, Ho AY, Ingram W, et al. Outcomes of alemtuzumab-based
reduced intensity conditioning stem cell transplantation using unre-
lated donors for myelodysplastic syndromes. Br J Haematol. 2006;135:
201-209.
A. Nakaya et al. / Biol Blood Marrow Transplant 20 (2014) 1553e1559 15593. Sorror ML, Giralt S, Sandmaier BM, et al. Hematopoietic cell trans-
plantation speciﬁc comorbidity index as an outcome predictor for pa-
tients with acute myeloid leukemia in ﬁrst remission: combined FHCRC
and MDACC experiences. Blood. 2007;110:4606-4613.
4. Sorror ML, Sandmaier BM, Storer B, et al. Comorbidity and disease
status based risk stratiﬁcation of outcomes among patients with acute
myeloid leukemia or myelodysplasia receiving allogeneic hematopoi-
etic cell transplantation. J Clin Oncol. 2007;25:4246-4254.
5. Boehm A, Sperr WR, Leitner G, et al. Comorbidity predicts survival in
myelodysplastic syndromes or secondary acute myeloid leukaemia
after allogeneic stem cell transplantation. Eur J Clin Invest. 2008;38:
945-952.
6. Majhail NS, Brunstein CG, McAvoy S, et al. Does the hematopoietic cell
transplantation speciﬁc comorbidity index predict transplant out-
comes? A validation study in a large cohort of umbilical cord blood and
matched related donor transplants. Biol Blood Marrow Transplant. 2008;
14:985-992.
7. Xhaard A, Porcher R, Chien JW, et al. Impact of comorbidity indexes on
non-relapse mortality. Leukemia. 2008;22:2062-2069.
8. Sorror ML, Storer B, Maloney D, et al. Outcomes after allogeneic he-
matopoietic cell transplantation with nonmyeloablative or myeloa-
blative conditioning regimens for treatment of lymphoma and chronic
lymphocytic leukemia. Blood. 2008;111:446-452.
9. Sorror ML, Storer B, Sandmaier BM, et al. Five-year follow-up of pa-
tients with advanced chronic lymphocytic leukemia treated with
allogeneic hematopoietic cell transplantation after nonmyeloablative
conditioning. J Clin Oncol. 2008;26:4912-4920.
10. Sorror ML, Storer B, Sandmaier BM, et al. Hematopoietic cell
transplantation-comorbidity index and Karnofsky performance status
are independent predictors of morbidity and mortality after allogeneic
nonmyeloablative hematopoietic cell transplantation. Cancer. 2008;
112:1992-2001.
11. Farina L, Bruno B, Patriarca F, et al. The hematopoietic cell trans-
plantation comorbidity index (HCT-CI) predicts clinical outcomes in
lymphoma and myeloma patients after reduced-intensity or non-
myeloablative allogeneic stem cell transplantation. Leukemia. 2009;
23:1131-1138.
12. Lim ZY, IngramW, Brand R, et al. Impact of pretransplant comorbidities
on alemtuzumab-based reduced-intensity conditioning allogeneic he-
matopoietic SCT for patients with high-risk myelodysplastic syndrome
and AML. Bone Marrow Transplant. 2010;45:633-639.
13. El Kourashy S, Williamson T, Chaudhry MA, et al. Inﬂuence of comor-
bidities on transplant outcomes in patients aged 50 years or more after
myeloablative conditioning incorporating ﬂudarabine, BU and ATG.
Bone Marrow Transplant. 2011;46:1077-1083.
14. MED-AB Forms Manual. Available at: http://www.ebmt.org/Contents/
Data-Management/Registrystructure/MED-ABdatacollectionforms/
Documents/MEDABFormsManual.pdf. Accessed: February 24, 2012.
15. Barba P, Pinana JL, Martino R, et al. Comparison of two pretransplant
predictive models and a ﬂexible HCT-CI using different cut off points to
determine low-, intermediate-, and high-risk groups: the ﬂexible HCT-
CI is the best predictor of NRM and OS in a population of patients
undergoing allo-RIC. Biol Blood Marrow Transplant. 2010;16:413-420.
16. Kovacsovics T, Park B, Hayes-Lattin B, et al. Applying the hematopoietic
cell transplantation-comorbidity index (HCT-CI) in myeloablative MUD
transplants predicts NRM and OS using a modiﬁed 2-tier scoring sys-
tem. Blood [ASH Annual Meeting] 2007;110. (Abstract 285).17. DeFor TE, Majhail NS, Weisdorf DJ, et al. A modiﬁed comorbidity index
for hematopoietic cell transplantation. Bone Marrow Transplant. 2010;
45:933-938.
18. Maruyama D, Fukuda T, Kato R, et al. Comparable antileukemia/lymphoma
effects in nonremission patients undergoing allogeneic hematopoietic cell
transplantation with a conventional cytoreductive or reduced-intensity
regimen. Biol Blood Marrow Transplant. 2007;13:932-941.
19. Kataoka K, Nannya Y, Ueda K, et al. Differential prognostic impact of
pretransplant comorbidity on transplant outcomes by disease status
and time from transplant: a single Japanese transplant center study.
Bone Marrow Transplant. 2010;45:513-520.
20. Takasaki H, Tanaka M, Tachibana T, et al. Prognostic factors in patients
aged 50 years or older undergoing allogeneic hematopoietic stem cell
transplantation for hematologic malignancy. Int J Hematol. 2012;95:
291-298.
21. Raimondi R, Tosetto A, Oneto R, et al. A. Validation of the hematopoi-
etic cell transplantation-speciﬁc comorbidity index: a prospective,
multicenter GITMO study. Blood. 2012;120:1327-1333.
22. Sorror ML, Logan BR, Zhu X, et al. Prospective validation of the pre-
dictive power of the hematopoietic cell transplantation comorbidity
index (HCT-CI) for HCT outcomes at US transplant centers: A Center For
International Blood And Marrow Transplant Research (CIBMTR) study.
Blood [ASH Annual Meeting] 2012;120. (Abstract 733).
23. Guilfoyle R, Demers A, Bredeson C, et al. Performance status, but not
the hematopoietic cell transplantation comorbidity index (HCT-CI),
predicts mortality at a Canadian transplant center. Bone Marrow
Transplant. 2009;43:133-139.
24. Pollack S, Steinberg S, Odom J, et al. Assessment of the hematopoietic
cell transplantation comorbidity index in non-Hodgkin lymphoma
patients receiving reduced-intensity allogeneic hematopoietic stem
cell transplantation. Biol Blood Marrow Transplant. 2009;15:223-230.
25. Terwey TH, Hemmati PG, Martus P, et al. A modiﬁed EBMT risk score
and the hematopoietic cell transplantation-speciﬁc comorbidity index
for pre-transplant risk assessment in adult acute lymphoblastic leu-
kemia. Haematologica. 2010;95:810-818.
26. Patel P, Sweiss K, Nimmagadda S, et al. Comorbidity index does not
predict outcome in allogeneic myeloablative transplants conditioned
with ﬂudarabine/i.v. busulfan (FluBu4). Bone Marrow Transplant. 2011;
46:1326-1330.
27. Birninger N, Bornhauser M, Schaich M, et al. The hematopoietic cell
transplantation-speciﬁc comorbidity index fails to predict outcomes in
high-risk AML patients undergoing allogeneic transplantation: inves-
tigation of potential limitations of the index. Biol Blood Marrow
Transplant. 2011;17:1822-1832.
28. Bokhari SW, Watson L, Nagra S, et al. Role of HCT-comorbidity index,
age and disease status at transplantation in predicting survival and
nonrelapse mortality in patients with myelodysplasia and leukemia
undergoing reduced-intensity conditioning hemopoietic progenitor
cell transplantation. Bone Marrow Transplant. 2012;47:528-534.
29. Castagna L, Fürst S, Marchetti N, et al. Retrospective analysis of com-
mon scoring systems and outcome in patients older than 60 years
treated with reduced-intensity conditioning regimen and alloSCT. Bone
Marrow Transplant. 2011;46:1000-1005.
30. Noriega V, de Lavallade H, Potter VT, et al. HCT-CI Is not a useful pre-
dictor for non relapse mortality in older patients (>60 years old)
receiving RIC transplant for AML or MDS. Blood [ASH Annual Meeting]
2012;120. (Abstract 721).
